論文

査読有り
2021年1月

Details on the effect of very short dual antiplatelet therapy after drug-eluting stent implantation in patients with high bleeding risk: insight from the STOPDAPT-2 trial.

Cardiovascular intervention and therapeutics
  • Hirotoshi Watanabe
  • Takenori Domei
  • Takeshi Morimoto
  • Masahiro Natsuaki
  • Hiroki Shiomi
  • Toshiaki Toyota
  • Masanobu Ohya
  • Satoru Suwa
  • Kensuke Takagi
  • Mamoru Nanasato
  • Yoshiki Hata
  • Masahiro Yagi
  • Nobuhiro Suematsu
  • Takafumi Yokomatsu
  • Itaru Takamisawa
  • Masayuki Doi
  • Toshiyuki Noda
  • Hideki Okayama
  • Yoshitane Seino
  • Tomohisa Tada
  • Hiroki Sakamoto
  • Kiyoshi Hibi
  • Mitsuru Abe
  • Kazuya Kawai
  • Koichi Nakao
  • Kenji Ando
  • Kengo Tanabe
  • Yuji Ikari
  • Keiichi Igarashi Hanaoka
  • Yoshihiro Morino
  • Ken Kozuma
  • Kazushige Kadota
  • Yutaka Furukawa
  • Yoshihisa Nakagawa
  • Takeshi Kimura
  • 全て表示

36
1
開始ページ
91
終了ページ
103
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1007/s12928-020-00651-9

Previously we briefly reported the effect of 1-month dual antiplatelet therapy (DAPT) for patients with high bleeding risk (HBR) receiving percutaneous coronary intervention (PCI) in the STOPDAPT-2 trial, but full analysis data have not been available. We conducted post hoc subgroup analysis regarding the effect of very short DAPT for HBR patients in STOPDAPT-2 trial. The primary endpoint was a 1-year composite of cardiovascular (cardiovascular death, myocardial infarction, definite stent thrombosis, or stroke) and bleeding (TIMI major/minor bleeding) outcomes. Major secondary endpoints were 1-year cardiovascular composite endpoint and bleeding endpoint. HBR was defined by the academic research consortium (ARC) HBR criteria. Among the 3009 study patients, 1054 (35.0%) were classified as HBR and 1955 (65.0%) were as non-HBR. There were no significant interactions between HBR/non-HBR subgroups and the assigned DAPT group on the primary endpoint (HBR; 3.48% vs. 5.98%, HR 0.57, 95% CI 0.32-1.03, and non-HBR; 1.81% vs. 2.36%, HR 0.78, 95% CI 0.42-1.45; P for interaction = 0.48), the major secondary cardiovascular endpoint (HBR; 3.07% vs. 4.03%, HR 0.77, 95% CI 0.40-1.48, and non-HBR; 1.41% vs. 1.61%, HR 0.89, 95% CI 0.43-1.84; P for interaction = 0.77), and the major secondary bleeding endpoint (HBR; 0.41% vs. 2.71%, HR 0.15, 95% CI 0.03-0.65, and non-HBR; 0.40% vs. 0.85%, HR 0.48, 95% CI 0.14-1.58; P for interaction = 0.22). In conclusion, the effects of 1-month DAPT for the primary and major secondary endpoints were consistent in HBR and non-HBR patients without any significant interactions. The benefit of 1-month DAPT in reducing major bleeding was numerically greater in HBR patients.Clinical trial registration Short and optimal duration of dual antiplatelet therapy after everolimus-eluting cobalt-chromium stent-2 [STOPDAPT-2]; NCT02619760.

リンク情報
DOI
https://doi.org/10.1007/s12928-020-00651-9
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/32086787
ID情報
  • DOI : 10.1007/s12928-020-00651-9
  • PubMed ID : 32086787

エクスポート
BibTeX RIS